Amoeba

Overview
Price performance
Financials
Research
Thematics

Amoéba is developing biological fungicides for treating diseases such as mildews and rusts, which have a major economic impact on the production globally of a wide range of crops. These novel fungicides are based on the characteristics of the Willaertia magna C2c Maky amoeba.

According to a report from Grand View Research, the global crop protection chemicals market was valued at $43.2bn in 2022 and is expected to expand at a CAGR of 5.6% from 2023 to 2030. Within this market, the biological segment is growing rapidly. A report published by P&S Intelligence noted that the global biocontrol agents market was worth c $4.9bn in 2021, and predicted that it would increase to $13.6bn by 2030. Management estimates that Amoéba’s addressable market size within the biological agents market is €1.6bn, expanding to €8bn if conventional fungicides are replaced by biological ones.

Latest Insights

Industrials |
Update

16.11.23

Amoeba — Biocontrol plant paves path to commercialisation

Industrials |
Update

22.05.23

Amoeba — Scaling up for commercialisation

Industrials |
Update

03.04.23

Amoeba — Building on an exceptional year

Industrials |
edison tv

13.03.23

Amoeba – executive interview

Visit Website

Sector

Industrials

Equity Analyst

Natalya Davies

Analyst

Key Management

Benoit Villers

Chairman
Fabrice Plasson

Founder
Jean-Francois Doucet

CEO

Balance Sheet

Forecast net debt (€m)

9.7

Forecast gearing ratio (%)

746

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	4.4	5.1	(29.3)
Relative	6.1	(1.6)	(33.2)
52 week high/low	€0.7/€0.4

Financials

FY23 marked a year of successful advancement for Amoéba: 1) the development of its biocontrol plant commenced, poised to achieve production of 40 tonnes per annum of W. magna lysate; 2) a third scientific article was published highlighting the efficacy of its biocontrol product; and 3) the company has announced a potential further application for W. magna lysate in cosmetic skincare. Although postponement of the construction of the Cavaillon plant has been confirmed in the short term, we do not expect this to hinder European marketing authorisation of AXPERA, which management hopes will be obtained by mid-2025.